41727-70-2

Upstream product

• 31106-74-8 1,3-dibromo-2-methoxy-5-nitrobenzene 
• 99-28-5 2,6-dibromo-4-nitrophenol 
• 104-94-9 4-methoxy-aniline 
• 609-21-2 2,6-dibromo-4-aminophenol 
• 63558-07-6 N-(3,5-dibromo-4-hydroxyphenyl)acetamide 
• 108761-48-4 N-(3,5-dibromo-4-methoxyphenyl)acetamide 
• 74-88-4 methyl iodide 
• 3460-20-6 1,2,3-tribromo-5-nitrobenzene 

Downstream Products

• 23742-75-8 1-(3,5-Dibromo-4-methoxy-phenyl)-3-(4-trifluoromethyl-phenyl)-urea 
• 38603-09-7 2,6-dibromoanisole 
• 89692-50-2 2,3,5,6-tetrabromo-4-methoxyaniline 
• 95970-19-7 2,3,6-tribromoanisole 
• 1363603-20-6 5-(1-(3,5-dibromo-4-methoxyphenyl)-1H-1,2,3-triazol-5-yl)-2-methoxyphenol 
• 1363603-26-2 2-(1-(3,5-dibromo-4-methoxyphenyl)-1H-1,2,3-triazol-5-yl)-5-methoxyphenol 
• 1363603-30-8 3-(1-(3,5-dibromo-4-methoxyphenyl)-1H-1,2,3-triazol-5-yl)-6-methoxybenzene-1,2-diol 
• 1380079-55-9 C₂₂H₂₇Br₂N₃O₃Si 
• 1380079-58-2 C₂₂H₂₇Br₂N₃O₃Si 
• 1380079-65-1 C₂₈H₄₁Br₂N₃O₄Si₂ 
• 1363602-98-5 5-azido-1,3-dibromo-2-methoxybenzene 
• 6161-55-3 2,3,5,6-tetrabromo-4-nitrophenol 
• 6161-56-4 4-nitro-2,3,5,6-tetrabromoanisole 
• 95970-18-6 2,3,5,6-tetrabromoanisole 

Relevant academic research and scientific papers

Application of quinoline derivatives of N-isostere tectorigenin in anti-hepatocarcinoma drugs

The invention discloses application of quinoline derivatives of N-isostere tectorigenin in anti-hepatocarcinoma drugs. The invention relates to the quinoline derivatives of the N-isostere tectorigenin, and the chemical structural formula of the quinoline

Synthesis method of quinoline derivatives

The invention discloses a synthesis method of quinoline derivatives. The method comprises steps shown in the description. According to the synthesis method of the quinoline derivatives, yield is high, the method is safe, environment-friendly, energy-savin

Synthetic method of 3-(4-methoxyphenyl)-6-methoxyl-4-chlorine-5, 7-dibromoquinoline

The invention discloses a synthetic method of 3-(4-methoxyphenyl)-6-methoxyl-4-chlorine-5, 7-dibromoquinoline. The synthetic method includes the following steps. The synthetic method has the advantages that the yield is high, safety, environment protectio

Synthesis method of quinoline derivative

The invention discloses a synthesis method of a quinoline derivative. The synthesis method includes the following steps in the specification. The method has high yield, is safe and environment-friendly, saves energy and reduces emission. The method is 90.

Synthesis method of quinoline derivative

The invention discloses a synthesis method of a quinoline derivative. The synthesis method includes the following steps in the specification. The method has high yield, is safe and environment-friendly, saves energy and reduces emission. The method is 90.

Synthesizing method of 3-(4-methoxyphenyl)-6-methyoxyl-4-chloro-5, 7-dibromoquinoline

The invention discloses a synthesizing method of a 3-(4-methoxyphenyl)-6-methyoxyl-4-chloro-5, 7-dibromoquinoline. The synthesizing method of the 3-(4-methoxyphenyl)-6-methyoxyl-4-chloro-5, 7-dibromoquinoline comprises the following steps of A. The synthe

Synthesis method of 3-(4-methoxyphenyl)-6-methoxy-4-chloro-5,7-dibromoquinoline

The invention discloses a synthesis method of 3-(4-methoxyphenyl)-6-methoxy-4-chloro-5,7-dibromoquinoline. The synthesis method comprises the following steps: the steps are shown in the description. The synthesis method disclosed by the invention has the

ANTIBACTERIAL COMPOUNDS

The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1

The antiproliferative activity on ovarian cancer (SK-OV-3) cells of a series of triazole-bridged combretastatin analogues (37, 38, 40-43) containing dihalogenation of the A-ring is reported, and compared with their trimethoxy analogues (5, 15, 39). It was found that dihalogenation with either bromine or iodine was a tolerated modification when compared to the parent compound combretastatin (CA-4, 1) and had less effect than B-ring modification on potency. These compounds exhibited G2/M arrest, and maintained antitubulin activity. Further assays on human umbilical vein endothelial cells (HUVECs) demonstrated the potential antivascular effects of these triazoles. Of particular note was a 3,5-diiodo-4-methoxyaryl triazole (43) which had promising 7-fold selectivity for HUVECs over ovarian cancer cells.

A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles

The combretastatins have been investigated for their antimitotic and antivascular properties, and it is widely postulated that a 3,4,5-trimethoxyaryl A-ring is essential to maintain potent activity. We have synthesized new tetrazole analogues (32a€"34), demonstrating that 3,5-dihalogenation can consistently increase potency by up to 5-fold when compared to the equivalent trimethoxy compound on human umbilical vein endothelial cells (HUVECs) and a range of cancer cells. Moreover, this increased potency offsets that lost by installing the tetrazole bridge into combretastatin A-4 (1), giving crystalline, soluble compounds that have low nanomolar activity, arrest cells in G2/M phase, and retain microtubule inhibitory activity. Molecular modeling has shown that optimized packing within the binding site resulting in increased Coulombic interaction may be responsible for this improved activity.